Inclusion and exclusion criteria US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Inclusion and exclusion criteria. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Inclusion and exclusion criteria US Medical PG Question 1: A study is funded by the tobacco industry to examine the association between smoking and lung cancer. They design a study with a prospective cohort of 1,000 smokers between the ages of 20-30. The length of the study is five years. After the study period ends, they conclude that there is no relationship between smoking and lung cancer. Which of the following study features is the most likely reason for the failure of the study to note an association between tobacco use and cancer?
- A. Late-look bias
- B. Latency period (Correct Answer)
- C. Confounding
- D. Effect modification
- E. Pygmalion effect
Inclusion and exclusion criteria Explanation: ***Latency period***
- **Lung cancer** typically has a **long latency period**, often **20-30+ years**, between initial exposure to tobacco carcinogens and the development of clinically detectable disease.
- A **five-year study duration** in young smokers (ages 20-30) is **far too short** to observe the development of lung cancer, which explains the false negative finding.
- This represents a **fundamental flaw in study design** rather than a bias—the biological timeline of disease development was not adequately considered.
*Late-look bias*
- **Late-look bias** occurs when a study enrolls participants who have already survived the early high-risk period of a disease, leading to **underestimation of true mortality or incidence**.
- Also called **survival bias**, it involves studying a population that has already been "selected" by survival.
- This is not applicable here, as the study simply ended before sufficient time elapsed for disease to develop.
*Confounding*
- **Confounding** occurs when a third variable is associated with both the exposure and outcome, distorting the apparent relationship between them.
- While confounding can affect study results, it would not completely eliminate the detection of a strong, well-established association like smoking and lung cancer in a properly conducted prospective cohort study.
- The issue here is temporal (insufficient follow-up time), not the presence of an unmeasured confounder.
*Effect modification*
- **Effect modification** (also called interaction) occurs when the magnitude of an association between exposure and outcome differs across levels of a third variable.
- This represents a **true biological phenomenon**, not a study design flaw or bias.
- It would not explain the complete failure to detect any association.
*Pygmalion effect*
- The **Pygmalion effect** (observer-expectancy effect) refers to a psychological phenomenon where higher expectations lead to improved performance in the observed subjects.
- This concept is relevant to **behavioral and educational research**, not to objective epidemiological studies of disease incidence.
- It has no relevance to the biological relationship between carcinogen exposure and cancer development.
Inclusion and exclusion criteria US Medical PG Question 2: A pharmaceutical corporation has asked you to assist in the development of a randomized controlled trial (RCT) to evaluate the response of renal cell carcinoma to a novel chemotherapeutic agent. Despite all of the benefits that an RCT has to offer, which of the following would make an RCT unacceptable with regard to study design?
- A. Proper treatment response is very common
- B. The treatment is not widespread in use
- C. The treatment does not represent the best known option
- D. The treatment is expensive
- E. The treatment has a known, adverse outcome (Correct Answer)
Inclusion and exclusion criteria Explanation: ***The treatment has a known, adverse outcome***
- If a treatment is already known to cause **significant harm** or an adverse outcome, it would be unethical to randomize patients to receive it, as this would expose them to unnecessary risk.
- **Ethical considerations** are paramount in clinical trial design; exposing patients to a known harmful treatment violates the principle of non-maleficence.
*Proper treatment response is very common*
- A high treatment response rate would make it **easier to detect a difference** between the novel agent and a control group, potentially requiring a smaller sample size.
- This scenario actually **facilitates** an RCT, as it increases the likelihood of demonstrating efficacy for the novel agent.
*The treatment is not widespread in use*
- The purpose of an RCT for a novel agent is precisely to evaluate its efficacy and safety to determine if it **deserves widespread use**.
- Lack of widespread use is the **starting point** for clinical trials, not a contraindication.
*The treatment does not represent the best known option*
- An RCT is often conducted to determine if a novel treatment is **superior or non-inferior** to existing standard-of-care treatments, even if the existing options are not considered "the best."
- Comparing a new treatment against a suboptimal current standard is a common and **valid objective** in clinical research to seek improvement.
*The treatment is expensive*
- The cost of a treatment is a **practical consideration** for healthcare systems and patients but does not inherently make an RCT unacceptable in terms of study design or ethics.
- **Cost-effectiveness** is often evaluated after efficacy and safety are established, usually in addition to the RCT or in subsequent studies.
Inclusion and exclusion criteria US Medical PG Question 3: An investigator is measuring the blood calcium level in a sample of female cross country runners and a control group of sedentary females. If she would like to compare the means of the two groups, which statistical test should she use?
- A. Chi-square test
- B. Linear regression
- C. t-test (Correct Answer)
- D. ANOVA (Analysis of Variance)
- E. F-test
Inclusion and exclusion criteria Explanation: ***t-test***
- A **t-test** is appropriate for comparing the means of two independent groups, such as the blood calcium levels between runners and sedentary females.
- It assesses whether the observed difference between the two sample means is statistically significant or occurred by chance.
*Chi-square test*
- The **chi-square test** is used to analyze categorical data to determine if there is a significant association between two variables.
- It is not suitable for comparing continuous variables like blood calcium levels.
*Linear regression*
- **Linear regression** is used to model the relationship between a dependent variable (outcome) and one or more independent variables (predictors).
- It aims to predict the value of a variable based on the value of another, rather than comparing means between groups.
*ANOVA (Analysis of Variance)*
- **ANOVA** is used to compare the means of **three or more independent groups**.
- Since there are only two groups being compared in this scenario, a t-test is more specific and appropriate.
*F-test*
- The **F-test** is primarily used to compare the variances of two populations or to assess the overall significance of a regression model.
- While it is the basis for ANOVA, it is not the direct test for comparing the means of two groups.
Inclusion and exclusion criteria US Medical PG Question 4: You are currently employed as a clinical researcher working on clinical trials of a new drug to be used for the treatment of Parkinson's disease. Currently, you have already determined the safe clinical dose of the drug in a healthy patient. You are in the phase of drug development where the drug is studied in patients with the target disease to determine its efficacy. Which of the following phases is this new drug currently in?
- A. Phase 4
- B. Phase 1
- C. Phase 2 (Correct Answer)
- D. Phase 0
- E. Phase 3
Inclusion and exclusion criteria Explanation: ***Phase 2***
- **Phase 2 trials** involve studying the drug in patients with the target disease to assess its **efficacy** and further evaluate safety, typically involving a few hundred patients.
- The question describes a stage after safe dosing in healthy patients (Phase 1) and before large-scale efficacy confirmation (Phase 3), focusing on efficacy in the target population.
*Phase 4*
- **Phase 4 trials** occur **after a drug has been approved** and marketed, monitoring long-term effects, optimal use, and rare side effects in a diverse patient population.
- This phase is conducted post-market approval, whereas the question describes a drug still in development prior to approval.
*Phase 1*
- **Phase 1 trials** primarily focus on determining the **safety and dosage** of a new drug in a **small group of healthy volunteers** (or sometimes patients with advanced disease if the drug is highly toxic).
- The question states that the safe clinical dose in a healthy patient has already been determined, indicating that Phase 1 has been completed.
*Phase 0*
- **Phase 0 trials** are exploratory, very early-stage studies designed to confirm that the drug reaches the target and acts as intended, typically involving a very small number of doses and participants.
- These trials are conducted much earlier in the development process, preceding the determination of safe clinical doses and large-scale efficacy studies.
*Phase 3*
- **Phase 3 trials** are large-scale studies involving hundreds to thousands of patients to confirm **efficacy**, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug to be used safely.
- While Phase 3 does assess efficacy, it follows Phase 2 and is typically conducted on a much larger scale before submitting for regulatory approval.
Inclusion and exclusion criteria US Medical PG Question 5: A 28-year-old male presents to his primary care physician with complaints of intermittent abdominal pain and alternating bouts of constipation and diarrhea. His medical chart is not significant for any past medical problems or prior surgeries. He is not prescribed any current medications. Which of the following questions would be the most useful next question in eliciting further history from this patient?
- A. "Does the diarrhea typically precede the constipation, or vice-versa?"
- B. "Is the diarrhea foul-smelling?"
- C. "Please rate your abdominal pain on a scale of 1-10, with 10 being the worst pain of your life"
- D. "Are the symptoms worse in the morning or at night?"
- E. "Can you tell me more about the symptoms you have been experiencing?" (Correct Answer)
Inclusion and exclusion criteria Explanation: ***Can you tell me more about the symptoms you have been experiencing?***
- This **open-ended question** encourages the patient to provide a **comprehensive narrative** of their symptoms, including details about onset, frequency, duration, alleviating/aggravating factors, and associated symptoms, which is crucial for diagnosis.
- In a patient presenting with vague, intermittent symptoms like alternating constipation and diarrhea, allowing them to elaborate freely can reveal important clues that might not be captured by more targeted questions.
*Does the diarrhea typically precede the constipation, or vice-versa?*
- While knowing the sequence of symptoms can be helpful in understanding the **pattern of bowel dysfunction**, it is a very specific question that might overlook other important aspects of the patient's experience.
- It prematurely narrows the focus without first obtaining a broad understanding of the patient's overall symptomatic picture.
*Is the diarrhea foul-smelling?*
- Foul-smelling diarrhea can indicate **malabsorption** or **bacterial overgrowth**, which are important to consider in some gastrointestinal conditions.
- However, this is a **specific symptom inquiry** that should follow a more general exploration of the patient's symptoms, as it may not be relevant if other crucial details are missed.
*Please rate your abdominal pain on a scale of 1-10, with 10 being the worst pain of your life*
- Quantifying pain intensity is useful for assessing the **severity of discomfort** and monitoring changes over time.
- However, for a patient with intermittent rather than acute, severe pain, understanding the **character, location, and triggers** of the pain is often more diagnostically valuable than just a numerical rating initially.
*Are the symptoms worse in the morning or at night?*
- Diurnal variation can be relevant in certain conditions, such as inflammatory bowel diseases where nocturnal symptoms might be more concerning, or functional disorders whose symptoms might be stress-related.
- This is another **specific question** that should come after gathering a more complete initial picture of the patient's symptoms to ensure no key information is overlooked.
Inclusion and exclusion criteria US Medical PG Question 6: A study seeks to investigate the therapeutic efficacy of treating asymptomatic subclinical hypothyroidism in preventing symptoms of hypothyroidism. The investigators found 300 asymptomatic patients with subclinical hypothyroidism, defined as serum thyroid-stimulating hormone (TSH) of 5 to 10 μU/mL with normal serum thyroxine (T4) levels. The patients were randomized to either thyroxine 75 μg daily or placebo. Both investigators and study subjects were blinded. Baseline patient characteristics were distributed similarly in the treatment and control group (p > 0.05). Participants' serum T4 and TSH levels and subjective quality of life were evaluated at a 3-week follow-up. No difference was found between the treatment and placebo groups. Which of the following is the most likely explanation for the results of this study?
- A. Observer effect
- B. Berkson bias
- C. Latency period (Correct Answer)
- D. Confounding bias
- E. Lead-time bias
Inclusion and exclusion criteria Explanation: ***Latency period***
- A **latency period** refers to the time between exposure to a cause (e.g., treatment) and the manifestation of its effects (e.g., symptom improvement). The study's **3-week follow-up is too short** to observe the therapeutic benefits of thyroxine in subclinical hypothyroidism.
- Levothyroxine (T4) has a **half-life of approximately 7 days**, and it typically takes **6-8 weeks or longer** for steady-state levels to be achieved and for clinical symptoms to improve. The slow onset of action for thyroid hormone replacement and the gradual nature of symptom resolution mean a longer observation period (typically 3-6 months) is needed to assess efficacy in hypothyroidism.
- The null results likely reflect insufficient follow-up time rather than lack of treatment effect.
*Observer effect*
- The **observer effect**, or Hawthorne effect, occurs when subjects change their behavior because they know they are being observed. This study used **double-blinding** (both investigators and subjects), which effectively minimizes the observer effect.
- The primary issue here is the lack of observed therapeutic effect due to timing, not a change in behavior due to observation.
*Berkson bias*
- **Berkson bias** is a form of selection bias that arises in case-control studies conducted in hospitals, where the probability of being admitted to the hospital can be affected by both exposure and disease.
- This study is a **randomized controlled trial**, not a case-control study, and the selection of participants does not illustrate this specific bias.
*Confounding bias*
- **Confounding bias** occurs when an extraneous variable is associated with both the exposure and the outcome, distorting the observed relationship. The study states that **baseline patient characteristics were similarly distributed (p > 0.05)**, indicating successful randomization and minimization of confounding.
- While confounding is a common concern in observational studies, the RCT design and reported baseline similarities make it unlikely to be the primary explanation for the null results compared to an insufficient follow-up period.
*Lead-time bias*
- **Lead-time bias** is a form of detection bias where early detection of a disease through screening appears to prolong survival, even if the treatment does not change the course of the disease.
- This study is evaluating the **efficacy of treatment** in asymptomatic individuals with subclinical hypothyroidism, not the effect of screening on survival, making lead-time bias irrelevant to these results.
Inclusion and exclusion criteria US Medical PG Question 7: In the study, all participants who were enrolled and randomly assigned to treatment with pulmharkimab were analyzed in the pulmharkimab group regardless of medication nonadherence or refusal of allocated treatment. A medical student reading the abstract is confused about why some participants assigned to pulmharkimab who did not adhere to the regimen were still analyzed as part of the pulmharkimab group. Which of the following best reflects the purpose of such an analysis strategy?
- A. To minimize type 2 errors
- B. To assess treatment efficacy more accurately
- C. To reduce selection bias (Correct Answer)
- D. To increase internal validity of study
- E. To increase sample size
Inclusion and exclusion criteria Explanation: ***To reduce selection bias***
- Analyzing participants in their originally assigned groups, regardless of adherence, is known as **intention-to-treat (ITT) analysis**.
- This method helps **preserve randomization** and minimizes **selection bias** that could arise if participants who did not adhere to treatment were excluded or re-assigned.
- **This is the most direct and specific purpose** of ITT analysis - preventing systematic differences between groups caused by post-randomization exclusions.
*To minimize type 2 errors*
- While ITT analysis affects statistical power, its primary purpose is not specifically to minimize **type 2 errors** (false negatives).
- ITT analysis may sometimes *increase* the likelihood of a type 2 error by diluting the treatment effect due to non-adherence.
*To assess treatment efficacy more accurately*
- ITT analysis assesses the **effectiveness** of *assigning* a treatment in a real-world setting, rather than the pure biological **efficacy** of the treatment itself.
- Efficacy is better assessed by a **per-protocol analysis**, which only includes compliant participants.
- ITT provides a more **conservative** and **pragmatic** estimate of treatment effect.
*To increase internal validity of study*
- While ITT analysis does contribute to **internal validity** by maintaining randomization, this is a **broader, secondary benefit** rather than the primary purpose.
- Internal validity encompasses many aspects of study design; ITT specifically addresses **post-randomization bias prevention**.
- The more precise answer is that ITT reduces **selection bias**, which is one specific threat to internal validity.
- Many other design features also contribute to internal validity (blinding, standardized protocols, etc.), making this option less specific.
*To increase sample size*
- ITT analysis includes all randomized participants, so it maintains the initial **sample size** that was randomized.
- However, the primary purpose is to preserve the integrity of randomization and prevent bias, not simply to increase the number of participants in the final analysis.
Inclusion and exclusion criteria US Medical PG Question 8: A randomized control double-blind study is conducted on the efficacy of 2 sulfonylureas. The study concluded that medication 1 was more efficacious in lowering fasting blood glucose than medication 2 (p ≤ 0.05; 95% CI: 14 [10-21]). Which of the following is true regarding a 95% confidence interval (CI)?
- A. If the same study were repeated multiple times, approximately 95% of the calculated confidence intervals would contain the true population parameter. (Correct Answer)
- B. The 95% confidence interval is the probability chosen by the researcher to be the threshold of statistical significance.
- C. When a 95% CI for the estimated difference between groups contains the value ‘0’, the results are significant.
- D. It represents the probability that chance would not produce the difference shown, 95% of the time.
- E. The study is adequately powered at the 95% confidence interval.
Inclusion and exclusion criteria Explanation: ***If the same study were repeated multiple times, approximately 95% of the calculated confidence intervals would contain the true population parameter.***
- This statement accurately defines the **frequentist interpretation** of a confidence interval (CI). It reflects the long-run behavior of the CI over hypothetical repetitions of the study.
- A 95% CI means that if you were to repeat the experiment many times, 95% of the CIs calculated from those experiments would capture the **true underlying population parameter**.
*The 95% confidence interval is the probability chosen by the researcher to be the threshold of statistical significance.*
- The **alpha level (α)**, typically set at 0.05 (or 5%), is the threshold for statistical significance (p ≤ 0.05), representing the probability of a Type I error.
- The 95% confidence level (1-α) is related to statistical significance, but it is not the *threshold* itself; rather, it indicates the **reliability** of the interval estimate.
*When a 95% CI for the estimated difference between groups contains the value ‘0’, the results are significant.*
- If a 95% CI for the difference between groups **contains 0**, it implies that there is **no statistically significant difference** between the groups at the 0.05 alpha level.
- A statistically significant difference (p ≤ 0.05) would be indicated if the 95% CI **does NOT contain 0**, suggesting that the intervention had a real effect.
*It represents the probability that chance would not produce the difference shown, 95% of the time.*
- This statement misinterprets the meaning of a CI and probability. The chance of not producing the observed difference is typically addressed by the **p-value**, not directly by the CI in this manner.
- A CI provides a **range of plausible values** for the population parameter, not a probability about the role of chance in producing the observed difference.
*The study is adequately powered at the 95% confidence interval.*
- **Statistical power** is the probability of correctly rejecting a false null hypothesis, typically set at 80% or 90%. It is primarily determined by sample size, effect size, and alpha level.
- A 95% CI is a measure of the **precision** of an estimate, while power refers to the **ability of a study to detect an effect** if one exists. They are related but distinct concepts.
Inclusion and exclusion criteria US Medical PG Question 9: A randomized controlled trial is conducted investigating the effects of different diagnostic imaging modalities on breast cancer mortality. 8,000 women are randomized to receive either conventional mammography or conventional mammography with breast MRI. The primary outcome is survival from the time of breast cancer diagnosis. The conventional mammography group has a median survival after diagnosis of 17.0 years. The MRI plus conventional mammography group has a median survival of 19.5 years. If this difference is statistically significant, which form of bias may be affecting the results?
- A. Recall bias
- B. Selection bias
- C. Misclassification bias
- D. Because this study is a randomized controlled trial, it is free of bias
- E. Lead-time bias (Correct Answer)
Inclusion and exclusion criteria Explanation: ***Lead-time bias***
- This bias occurs when a screening test diagnoses a disease earlier, making **survival appear longer** even if the actual time of death is unchanged.
- In this scenario, adding **MRI** may detect breast cancer at an earlier, asymptomatic stage, artificially extending the apparent survival duration from diagnosis without necessarily changing the ultimate prognosis.
*Recall bias*
- **Recall bias** applies to retrospective studies where subjects are asked to recall past exposures, and those with the outcome are more likely to remember potential exposures.
- It's irrelevant here as this is a **prospective randomized controlled trial** studying objective survival outcomes, not subjective past recollections.
*Selection bias*
- **Selection bias** occurs when participants are not randomly assigned to groups, leading to systematic differences between the groups influencing the outcome.
- This study is a **randomized controlled trial**, which is designed to minimize selection bias by ensuring participants have an equal chance of being assigned to either treatment arm.
*Misclassification bias*
- **Misclassification bias** happens when either the exposure or the outcome is incorrectly categorized, leading to erroneous associations.
- This study uses objective diagnostic imaging and survival data, thus reducing the likelihood of **misclassification of diagnosis or survival status**.
*Because this study is a randomized controlled trial, it is free of bias*
- While **randomized controlled trials (RCTs)** are considered the **gold standard** for minimizing bias, they are not entirely immune to all forms of bias.
- **Lead-time bias**, for instance, can still occur in RCTs involving screening or early diagnosis, as seen in this example, and other biases like **information bias** or **reporting bias** can also arise.
Inclusion and exclusion criteria US Medical PG Question 10: A group of bariatric surgeons are investigating a novel surgically-placed tube that drains a portion of the stomach following each meal. They are interested in studying its efficacy in facilitating weight loss in obese adults with BMIs > 40 kg/m2 who have failed to lose weight through non-surgical options. After randomizing 150 patients to undergoing the surgical tube procedure and 150 patients to non-surgical weight loss options (e.g., diet, exercise), the surgeons found that, on average, participants in the surgical treatment group lost 15% of their total body weight in comparison to 4% in the non-surgical group. Which of the following statistical tests is an appropriate initial test to evaluate if this difference in weight loss between the two groups is statistically significant?
- A. Kaplan-Meier analysis
- B. Paired two-sample t-test
- C. Multiple linear regression
- D. Pearson correlation coefficient
- E. Unpaired two-sample t-test (Correct Answer)
Inclusion and exclusion criteria Explanation: ***Unpaired two-sample t-test***
- The goal is to compare the **means of two independent groups** (surgical vs. non-surgical) on a continuous outcome (percentage of weight loss).
- An unpaired t-test is ideal for determining if the **observed difference between these two group means** is statistically significant.
*Kaplan-Meier analysis*
- This analysis is used to estimate and compare **survival curves** or time-to-event data between groups.
- It is not suitable for comparing the **mean weight loss** between two independent groups.
*Paired two-sample t-test*
- A paired t-test is used when comparing two measurements from the **same individuals** or **matched pairs**.
- Here, the two groups are distinct and independent, not paired in any way.
*Multiple linear regression*
- This is used to model the **relationship between a dependent variable** and **two or more independent variables**.
- While useful for predicting weight loss based on multiple factors, it's not the most direct or initial test for simply comparing the mean weight loss between two groups.
*Pearson correlation coefficient*
- The Pearson correlation coefficient measures the **strength and direction of a linear relationship between two continuous variables**.
- It does not compare the means of two independent groups, but rather assesses the **degree to which two variables change together**.
More Inclusion and exclusion criteria US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
